Evidence map›Paper›PMID 40892331›Full record

ArticleLa Radiologia medica2025

Radiomics-based prediction of microsatellite instability in colorectal cancer: a non-invasive approach to treatment stratification.

Davide Mallardi, Ginevra Danti, Antonio Galluzzo, Linda Calistri, Diletta Cozzi, Daniele Lavacchi, Daniele Rossini, Lorenzo Antonuzzo, Sebastiano Paolucci, Simone Busoni and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in La Radiologia medica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Davide MallardiDepartment of Radiology, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy. mallardidav@gmail.com.ORCID http://orcid.org/0009-0006-6993-4559
Ginevra DantiDepartment of Radiology, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.
Antonio GalluzzoDepartment of Radiology, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.
Linda CalistriDepartment of Radiology, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.
Diletta CozziDepartment of Radiology, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.
Daniele LavacchiClinical Oncology Unit, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.
Daniele RossiniDepartment of Experimental and Clinical Medicine, University of Florence, Largo Brambilla 3, 50134, Florence, Italy.
Lorenzo AntonuzzoClinical Oncology Unit, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.
Sebastiano PaolucciDepartment of Health Physics, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.
Simone BusoniDepartment of Health Physics, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.
Francesca CastiglionePathology Unit, Department of Experimental and Clinical Medicine, University of Florence, Largo Brambilla 3, 50134, Florence, Italy.
Luca MesseriniPathology Unit, Department of Experimental and Clinical Medicine, University of Florence, Largo Brambilla 3, 50134, Florence, Italy.
Fabio CianchiDepartment of Experimental and Clinical Medicine, University of Florence, Largo Brambilla 3, 50134, Florence, Italy.
Vittorio MieleDepartment of Radiology, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeManagement of colorectal cancer (CRC) is determined by the stage of the disease and molecular features, such as microsatellite instability (MSI). MSI-high/deficient mismatch repair (MSI-H/dMMR) tumors respond better to immunotherapy but poorly to 5-FU-based treatments. With increasing use of neoadjuvant chemotherapy there is interest in developing non-invasive, radiomics models based on preoperative contrast-enhanced CT scans to predict MSI status and support personalized therapy. MATERIAL AND

methodsAdult patients diagnosed with CRC who underwent pre-treatment staging with contrast-enhanced CT and had known MSI status were retrospectively analyzed. Portal venous phase images were assessed. Two radiologists, blinded to MSI status, manually segmented tumor regions on CT images. Radiomic features and statistical modeling were used to develop a predictive model for identifying the MSI-H phenotype.

resultsAnalysis was conducted on 54 adult CRC patients who had undergone staging CT scans with known MSI status. Two different models were built considering different brands of CT machines. Twenty statistically significant radiomic features from the portal venous phase of CT images able to differentiate MSI from microsatellite stable (MSS) patients were selected for each model. LASSO regression was applied, selecting features for model construction. The best model's performance demonstrated an area under the ROC curve of 0.844 (95% CI = 0.73-0.96 DeLong, p < 0,05).

conclusionThe results demonstrate the potential of the radiomics model as a non-invasive, cost-effective tool for MSI evaluation, guiding CRC therapy. It aids in identifying patients who would benefit from immunotherapy or chemotherapy, supporting the therapeutic shift from postoperative to preoperative treatment.

Indexed as

Colorectal NeoplasmsMicrosatellite InstabilityTomography, X-Ray ComputedAdultAgedAged, 80 and overContrast MediaFemaleHumansMaleMiddle AgedNeoadjuvant TherapyNeoplasm StagingPredictive Value of TestsRadiomicsRetrospective StudiesContrast MediaColonColon cancerImmunotherapyMicrosatellite instabilityRadiomic model

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.